A cross-party committee of British lawmakers has called for substantially increased access to the weight-loss medication Mounjaro through the National Health Service in England, arguing that current plans fall short of patient needs.
The Health Committee stated that providing the injection to 220,000 people by 2028 represents inadequate provision, covering approximately 6% of those deemed eligible for the treatment. The MPs characterized this approach as “woefully small” and lacking sufficient ambition. The limited NHS availability has contributed to a situation where over one million individuals have pursued private purchases of weight-loss medications, including Mounjaro and Wegovy, creating a system in which access correlates with ability to pay.
The NHS currently operates under a 12-year implementation timeline for Mounjaro distribution, though this plan is under review. Providing the medication to all 2.8 million eligible individuals immediately would require an estimated £15.2 billion investment over five years. The committee recommended that the NHS adopt practices used by private providers, particularly digital platforms for patient support and monitoring, to reduce administrative costs and improve efficiency. MPs suggested that streamlining patient support processes could lower expenses while making financial sense given that obesity costs the broader economy approximately £75 billion annually.
The committee also addressed related concerns about weight-loss treatment access. It called for enforcement measures against illegal markets for weight-loss medications, recommending public awareness campaigns about associated dangers and regulatory review of online advertising. The MPs criticized the overall design and resourcing of NHS weight-loss services, advocating for improved access to dietary programs, lifestyle interventions, and bariatric surgery. NHS England responded by indicating it was exploring acceleration options for weight-loss medication distribution while maintaining current prioritization for patients with the most severe conditions.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI